CHRISTINA GANT: Open Payments
NPI 1285732479 · SIOUX FALLS, SD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$675 in 41 payments from 19 companies in 2025. Trend: 2023 $487 · 2024 $523 · 2025 $675
Food & beverage: $615Education: $59
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. | 15 | $155 |
| Novartis Pharmaceuticals Corporation | 3 | $67 |
| AstraZeneca Pharmaceuticals LP | 2 | $57 |
| Janssen Biotech, Inc. | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| PFIZER INC. | 2 | $32 |
| E.R. Squibb & Sons, L.L.C. | 2 | $31 |
| Gilead Sciences, Inc. | 2 | $31 |
| Incyte Corporation | 1 | $27 |
| Deciphera Pharmaceuticals Inc. | 1 | $24 |
Products named: ENHERTU, REBLOZYL, KISQALI, FRUZAQLA, Trodelvy, MONJUVI, QINLOCK, BRUKINSA.
Industry payments across SD — which companies pay providers there.
